BMPR2 Antibody - #AF5383

(4)   (7)  
Product: BMPR2 Antibody
Catalog: AF5383
Description: Rabbit polyclonal antibody to BMPR2
Application: WB IHC IF/ICC
Reactivity: Human, Mouse, Rat, Monkey
Prediction: Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
Mol.Wt.: 115 kDa; 115kD(Calculated).
Uniprot: Q13873
RRID: AB_2837868

View similar products>>

   Size Price Inventory
 100ul $280 In stock
 200ul $350 In stock

Lead Time: Same day delivery

For pricing and ordering contact:
Local distributors
Related Downloads
MSDS
Data Sheet
COA
Protocols
WB Handbook
IHC Protocol
IF/ICC Protocol

Product Info

Source:
Rabbit
Application:
WB 1:500-1:2000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

Reactivity:
Human,Mouse,Rat,Monkey
Prediction:
Bovine(100%), Horse(100%), Sheep(100%), Rabbit(100%), Dog(92%), Chicken(100%), Xenopus(100%)
Clonality:
Polyclonal
Specificity:
BMPR2 Antibody detects endogenous levels of total BMPR2.
RRID:
AB_2837868
Cite Format: Affinity Biosciences Cat# AF5383, RRID:AB_2837868.
Conjugate:
Unconjugated.
Purification:
The antiserum was purified by peptide affinity chromatography using SulfoLink™ Coupling Resin (Thermo Fisher Scientific).
Storage:
Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.
Alias:

Fold/Unfold

BMP type II receptor; BMP type-2 receptor; BMPR 2; BMPR 3; BMPR II; BMPR-2; BMPR-II; Bmpr2; BMPR2_HUMAN; BMPR3; BMPRII; BMR 2; BMR2; Bone morphogenetic protein receptor type 2; Bone morphogenetic protein receptor type II; Bone morphogenetic protein receptor type-2; Bone morphogenic protein receptor type II serine threonine kinase; BRK 3; BRK3; PPH 1; PPH1; Serine threonine kinase type II activin receptor like kinase; T ALK; TALK; Type II activin receptor like kinase;

Immunogens

Immunogen:
Uniprot:

Q13873(BMPR2_HUMAN) >>Visit HPA database.

Gene(ID):
BMPR2(659)
Expression:
Q13873 BMPR2_HUMAN:

Highly expressed in heart and liver.

Description:
On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators.
Sequence:
MTSSLQRPWRVPWLPWTILLVSTAAASQNQERLCAFKDPYQQDLGIGESRISHENGTILCSKGSTCYGLWEKSKGDINLVKQGCWSHIGDPQECHYEECVVTTTPPSIQNGTYRFCCCSTDLCNVNFTENFPPPDTTPLSPPHSFNRDETIIIALASVSVLAVLIVALCFGYRMLTGDRKQGLHSMNMMEAAASEPSLDLDNLKLLELIGRGRYGAVYKGSLDERPVAVKVFSFANRQNFINEKNIYRVPLMEHDNIARFIVGDERVTADGRMEYLLVMEYYPNGSLCKYLSLHTSDWVSSCRLAHSVTRGLAYLHTELPRGDHYKPAISHRDLNSRNVLVKNDGTCVISDFGLSMRLTGNRLVRPGEEDNAAISEVGTIRYMAPEVLEGAVNLRDCESALKQVDMYALGLIYWEIFMRCTDLFPGESVPEYQMAFQTEVGNHPTFEDMQVLVSREKQRPKFPEAWKENSLAVRSLKETIEDCWDQDAEARLTAQCAEERMAELMMIWERNKSVSPTVNPMSTAMQNERNLSHNRRVPKIGPYPDYSSSSYIEDSIHHTDSIVKNISSEHSMSSTPLTIGEKNRNSINYERQQAQARIPSPETSVTSLSTNTTTTNTTGLTPSTGMTTISEMPYPDETNLHTTNVAQSIGPTPVCLQLTEEDLETNKLDPKEVDKNLKESSDENLMEHSLKQFSGPDPLSSTSSSLLYPLIKLAVEATGQQDFTQTANGQACLIPDVLPTQIYPLPKQQNLPKRPTSLPLNTKNSTKEPRLKFGSKHKSNLKQVETGVAKMNTINAAEPHVVTVTMNGVAGRNHSVNSHAATTQYANGTVLSGQTTNIVTHRAQEMLQNQFIGEDTRLNINSSPDEHEPLLRREQQAGHDEGVLDRLVDRRERPLEGGRTNSNNNNSNPCSEQDVLAQGVPSTAADPGPSKPRRAQRPNSLDLSATNVLDGSSIQIGESTQDGKSGSGEKIKKRVKTPYSLKRWRPSTWVISTESLDCEVNNNGSNRAVHSKSSTAVYLAEGGTATTMVSKDIGMNCL

Predictions

Predictions:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species
Results
Score
Horse
100
Bovine
100
Sheep
100
Xenopus
100
Chicken
100
Rabbit
100
Dog
92
Pig
0
Zebrafish
0
Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

PTMs - Q13873 As Substrate

Site PTM Type Enzyme
K219 Acetylation
Y247 Phosphorylation
Y314 Phosphorylation
S336 Phosphorylation
S355 Phosphorylation
T359 Phosphorylation
S375 Phosphorylation
T379 Phosphorylation
S513 Phosphorylation
S515 Phosphorylation
K539 Ubiquitination
Y546 Phosphorylation
S547 Phosphorylation
S550 Phosphorylation
Y551 Phosphorylation
K564 Ubiquitination
S574 Phosphorylation
T575 Phosphorylation
S586 Phosphorylation
Y589 Phosphorylation
S680 Phosphorylation
S681 Phosphorylation
Y708 Phosphorylation
S757 Phosphorylation
K763 Ubiquitination
T803 Phosphorylation
T805 Phosphorylation
Y825 Phosphorylation
S862 Phosphorylation
S863 Phosphorylation
T977 Phosphorylation
Y979 Phosphorylation
S980 Phosphorylation

Research Backgrounds

Function:

On ligand binding, forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. Type II receptors phosphorylate and activate type I receptors which autophosphorylate, then bind and activate SMAD transcriptional regulators. Binds to BMP7, BMP2 and, less efficiently, BMP4. Binding is weak but enhanced by the presence of type I receptors for BMPs. Mediates induction of adipogenesis by GDF6.

Subcellular Location:

Cell membrane>Single-pass type I membrane protein.

Extracellular region or secreted Cytosol Plasma membrane Cytoskeleton Lysosome Endosome Peroxisome ER Golgi apparatus Nucleus Mitochondrion Manual annotation Automatic computational assertionSubcellular location
Tissue Specificity:

Highly expressed in heart and liver.

Subunit Structure:

Interacts with GDF5.

Family&Domains:

Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.

Research Fields

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells.   (View pathway)

· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction.   (View pathway)

· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway.   (View pathway)

· Environmental Information Processing > Signal transduction > Hippo signaling pathway.   (View pathway)

· Human Diseases > Cancers: Overview > MicroRNAs in cancer.

· Organismal Systems > Development > Axon guidance.   (View pathway)

References

1). Magnesium-enriched microenvironment promotes odontogenic differentiation in human dental pulp stem cells by activating ERK/BMP2/Smads signaling. Stem Cell Research & Therapy, 2019 (PubMed: 31823825) [IF=7.5]

Application: WB    Species: Human    Sample: DPSCs

Fig. 6 The ERK and BMP2 signaling pathway is activated by high extracellular Mg2+ in DPSCs during odontogenic differentiation. a ERK phosphorylation was significantly enhanced in DPSCs treated with 1 mM, 5 mM, and 10 mM Mg2+ compared with the 0 mM Mg2+ group, but p38 and JNK phosphorylation amounts were unchanged. b ERK phosphorylation was reduced by 2-APB. c Consistently, the protein levels of BMP2, BMPR1, and phosphorylated Smad1/5/9 were significantly increased in DPSCs exposed to high extracellular Mg2+. d BMP2, BMPR1, and phosphorylated Smad1/5/9 protein amounts were decreased by 2-APB
2). Exosomal miR-100-5p inhibits osteogenesis of BMSCs and angiogenesis of VECs by suppressing BMPR2/Smad1/5/9 signaling pathway. Stem Cell Research & Therapy, 2021 (PubMed: 34256859) [IF=7.5]

Application: WB    Species: Human    Sample: HUVECs

Fig. 6 MiR-100-5p inhibited osteogenesis of hBMSCs and angiogenesis of HUVECs, promoting adipogenesis of hBMSCs. A RT-PCR was used to detect the expression of miR-100-5p in hBMSCs. B WB was used to detect the expression of BMPR2, collagen type 1, OCN, RUNX2, ALP, OPN, and PPARγ in hBMSCs. C The expression of miR-100-5p in HUVECs. D WB was used to measure the expression of BMPR2, FGF2, and VEGFA in HUVECs. E ALP staining of hBMSCs (scale bar = 100 μm). F Alizarin Red S staining of hBMSCs after cultured in ODM for 14 days. G Oil Red O staining of hBMSCs (scale bar = 50 μm). H Tube formation assay of HUVECs (scale bar = 200 μm). NM-CTL, controls for differentiation. *P < 0.05, versus NC group; #P < 0.05, versus agomiR-100-5p group. All data were expressed as mean ± SEM
3). RGMa Participates in the Blood–Brain Barrier Dysfunction Through BMP/BMPR/YAP Signaling in Multiple Sclerosis. Frontiers in Immunology, 2022 (PubMed: 35664003) [IF=7.3]

Application: WB    Species: Mice    Sample: brain and spinal cord

Figure 3 BMP2 and BMPR II expression in EAE mice. (A–F) BMP2 and BMPR II in the brain and spinal cord were both upregulated in the 14- and 21-day group compared with the control group. BMP2 and BMPR II in both the brain and spinal cord were significantly higher in the 21-day than the 0-day groups (n = 4, error bar: SEM; * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, one-way ANOVA with Bonferroni). (G–J) Immunofluorescence showed BMP2 and BMPR II were located in CD31+ endothelial cells in both the brain cortex and the white matter of the spinal cord. Scale bar: 50 µm (brain), 25 µm (spinal cord).
4). Activation of the BMP2-SMAD1-CGRP pathway in dorsal root ganglia contributes to bone cancer pain in a rat model. Heliyon, 2024 [IF=4.0]

Application: WB    Species: Rat    Sample:

Fig. 4. BMPRs are involved in BCP. (A) Western blot analysis of BMPR1B levels in the L3-L5 DRG ipsilateral to the tumor-bearing bone in rats with BCP versus sham controls on day 21. n = 8 per group. ***p = 0.0002 (Mann Whitney test). Top: representative Western blot. Bottom: quantification of BMPR1B expression levels. (B) Western blot analysis of BMPR2 levels in rats with BCP versus sham control rats. n = 8 per group. *p = 0.0281 (Mann Whitney test). Top: representative Western blot. Bottom: quantification of BMPR2 expression levels. (C) Paw withdrawal mechanical threshold (PWMT) in BCP animals given LDN193189 or vehicle (****p < 0.0001); two-way ANOVA with the Geisser-Greenhouse correction and Tukey's multiple comparisons test. (D) Limb use scores in BCP animals given LDN193189 or vehicle (*p = 0.0168, **p = 0.0062, ***p = 0.0005 and 0.0004 for day 11 and day 14 respectively, ****p < 0.0001); two-way ANOVA with the Geisser-Greenhouse correction and Tukey's multiple comparisons test.

Restrictive clause

 

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.